
Background: Clinical misdiagnosis, particularly at early disease stages, is a roadblock to finding new therapies for Lewy body disorders. Biopsy of a peripheral site might provide improved diagnostic accuracy. Previously, we reported, from both autopsy and needle biopsy, a high prevalence of submandibular gland synucleinopathy in Parkinson’s disease (PD). Here, we report on an extension of these studies to subjects with dementia with Lewy bodies (DLB) and other Lewy body disorders in 228 autopsied subjects from the Arizona Study of Aging and Neurodegenerative Disorders. Objective: To provide an estimate of the prevalence of histological synucleinopathy in the submandibular glands of subjects with PD and other Lewy body disorders. Methods: Submandibular gland sections from autopsied subjects were stained with an immunohistochemical method for α-synuclein phosphorylated at serine 129. Included were 146 cases with CNS Lewy-type synucleinopathy (LTS), composed of 46 PD, 28 DLB, 14 incidental Lewy body disease (ILBD), 33 Alzheimer’s disease with Lewy bodies (ADLB) and 2 with progressive supranuclear palsy and Lewy bodies (PSPLB). Control subjects included 79 normal elderly, 15 AD, 12 PSP, 2 conticobasal degeneration (CBD) and 2 multiple system atrophy (MSA). Results: Submandibular gland LTS was found in 42/47 (89%) of the PD subjects, 20/28 (71%) DLB, 4/33 (12%) ADLB and 1/9 (11%) ILBD subjects but none of the 110 control subjects. Conclusions: These results provide support for further clinical trials of in vivo submandibular gland diagnostic biopsy for PD and DLB. An accurate peripheral biopsy diagnosis would assist subject selection for clinical trials and could also be used to verify other biomarkers.
Arizona Parkinson's Disease Consortium, Lewy Body Disease, Male, Aging, diagnosis, Lewy Body Dementia, Biopsy, Neurodegenerative, Clinical Research, Submandibular Gland Diseases, Acquired Cognitive Impairment, 80 and over, Prevalence, Humans, Aged, Aged, 80 and over, screening and diagnosis, therapy, Parkinson's Disease, Biomedical and Clinical Sciences, Neurosciences, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), clinical trial, Parkinson Disease, Immunohistochemistry, Brain Disorders, 4.1 Discovery and preclinical testing of markers and technologies, Detection, Early Diagnosis, Neurological, alpha-Synuclein, biomarker, Dementia, pathology, Female, Biochemistry and Cell Biology, Autopsy
Arizona Parkinson's Disease Consortium, Lewy Body Disease, Male, Aging, diagnosis, Lewy Body Dementia, Biopsy, Neurodegenerative, Clinical Research, Submandibular Gland Diseases, Acquired Cognitive Impairment, 80 and over, Prevalence, Humans, Aged, Aged, 80 and over, screening and diagnosis, therapy, Parkinson's Disease, Biomedical and Clinical Sciences, Neurosciences, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), clinical trial, Parkinson Disease, Immunohistochemistry, Brain Disorders, 4.1 Discovery and preclinical testing of markers and technologies, Detection, Early Diagnosis, Neurological, alpha-Synuclein, biomarker, Dementia, pathology, Female, Biochemistry and Cell Biology, Autopsy
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 55 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
